Goldman Sachs analyst Richard Law moved shares of Bicara Therapeutics (BCAX) to Neutral rating and $14 price target from the firm’s Early-Stage Biotech designation. The company’s ficerafusp alfa combination is an improvement over the standard of care but unlikely has best-in-class potential, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics announces inducement grants
- Bicara Therapeutics initiated with an Outperform at Citizens
- BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
- Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
- Bicara Sets Phase 3 Path for Ficerafusp Alfa